what is the difference between glp-1 and tirzepatide Bridging gap GLP1-receptor agonists cardiovascular outcomes: evidence for the role of | Cardiovascular Diabetology Effects of tirzepatide, a dual

Learn from world-class conversations with leading endocrinologists, metabolic researchers, and healthcare innovators

Clear, particulate-free solution

Tesofensine is typically administered orally in capsule form, with daily doses ranging from 0.25 mg to 1 mg

However, the top specialists at Blue Fin Vision employ various approaches that may benefit certain patients: Acute Management: Immediate discontinuation of GLP-1 medication when NAION is confirmed Corticosteroid therapy in selected cases Comprehensive cardiovascular risk factor assessment Secondary Prevention: Aggressive management of vascular risk factors Blood pressure optimisation Aspirin therapy consideration Regular monitoring of the unaffected eye Risk Factors and Patient Selection Certain patient populations require particularly careful consideration before initiating GLP-1 therapy: High-Risk Patients: Individuals with pre-existing diabetic retinopathy Patients with poorly controlled diabetes and high HbA1c levels Those with cardiovascular risk factors Elderly patients Individuals with optic nerve head abnormalities The experienced team at Blue Fin Vision collaborates closely with endocrinologists and primary care physicians to ensure appropriate patient selection and monitoring protocols

As we await more definitive guidance, patients and healthcare providers must be well-informed and proactive in their treatment decisions